The headline reads as positive (89% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › NVS
Novartis Ag (NVS) stock analysis
WEAK BUY 13% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Novartis Ag (NVS) WEAK BUY with 13% confidence at a price of $161.10. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$161.10
Technical picture
The 14-day RSI is 76, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.1x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $165.43 and the swing low is $142.25; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 3.85, which looks expensive relative to its growth.
The company reports a profit margin of 17.5% and revenue growth of +4.7%.
In its latest quarter it earned $2.46 per share, which beat the $2.24 analysts expected, with revenue +4.7% year over year.
Wall Street's average rating is 2.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "hold", with an average price target of $155.29.
The next earnings report is expected around Feb 3, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $161.10, a target of $165.29 (+2.6%) and a stop-loss at $154.39 (-4.2%).
That is a reward-to-risk ratio of about 0.6 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 9, 2026 whatever the price does.
Entry$161.10
Target$165.29
Stop-loss$154.39
Reassess byNov 9, 2026
The model's one-paragraph read
Leans BUY — composite score +0.13 (WEAK BUY). Technicals: RSI 76.36, MACD bullish, price above SMA50. Fundamentals: PEG 3.85, margin 17.5%, revenue growth 4.7%. Financial results: YoY revenue +4.7%, last EPS surprise +9.8%, next earnings 2027-02-03. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Suggested levels: entry $161.1, target $165.29, stop-loss $154.39, exit by 2026-11-09 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for NVS
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | WEAK BUY | 13% | $161.10 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on NVS
Oct 30, 2026 · Eli Lillys tirzepatide outperforms big pharma companies in Q3
- Oct 30, 2026: Earnings roundup: Lillys unwavering momentum, Novartis rebound and GSKs waiting game (BioPharma Dive)
- Oct 30, 2026: Eli Lillys tirzepatide outperforms big pharma companies in Q3 (Pharmaceutical Technology)
Frequently asked questions
Is NVS a buy right now?
As of Oct 30, 2026, our automated model rates Novartis Ag (NVS) WEAK BUY with 13% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for NVS?
The model's most recent plan targets $165.29 with a stop-loss at $154.39, from an entry near $161.10.
When does Novartis Ag report earnings next?
The next earnings report is expected around Feb 3, 2027.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.